Northwest Biotherapeutics Valuation
| NWBO Stock | USD 0.29 0.01 3.33% |
Northwest Biotherapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Northwest Biotherapeutics from analyzing the firm fundamentals such as Shares Outstanding of 1.05 B, return on asset of -1.26, and Operating Margin of (54.95) % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Northwest Biotherapeutics' price fluctuation is out of control at this time. Calculation of the real value of Northwest Biotherapeutics is based on 3 months time horizon. Increasing Northwest Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Northwest otc stock is determined by what a typical buyer is willing to pay for full or partial control of Northwest Biotherapeutics. Since Northwest Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Northwest OTC Stock. However, Northwest Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.29 | Real 0.24 | Hype 0.25 | Naive 0.31 |
The intrinsic value of Northwest Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Northwest Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Northwest Biotherapeutics helps investors to forecast how Northwest otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Northwest Biotherapeutics more accurately as focusing exclusively on Northwest Biotherapeutics' fundamentals will not take into account other important factors: Northwest Biotherapeutics Total Value Analysis
Northwest Biotherapeutics is now forecasted to have valuation of 1.03 B with market capitalization of 705.3 M, debt of 25.16 M, and cash on hands of 9.43 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Northwest Biotherapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.03 B | 705.3 M | 25.16 M | 9.43 M |
Northwest Biotherapeutics Investor Information
The company recorded a loss per share of 0.06. Northwest Biotherapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 26th of September 2012. Based on the key indicators related to Northwest Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Northwest Biotherapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Northwest Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Northwest Biotherapeutics has an asset utilization ratio of 2.5 percent. This suggests that the OTC Stock is making $0.025 for each dollar of assets. An increasing asset utilization means that Northwest Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Northwest Biotherapeutics Ownership Allocation
Northwest Biotherapeutics maintains a total of 1.05 Billion outstanding shares. Northwest Biotherapeutics secures 10.04 % of its outstanding shares held by insiders and 0.23 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Northwest Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 1 M. Net Income was 179.13 M with profit before overhead, payroll, taxes, and interest of 1 M.About Northwest Biotherapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Northwest Biotherapeutics. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Northwest Biotherapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Northwest Biotherapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Northwest Biotherapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Northwest Biotherapeutics. We calculate exposure to Northwest Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Northwest Biotherapeutics's related companies.Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
8 Steps to conduct Northwest Biotherapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Northwest Biotherapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Northwest Biotherapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Northwest Biotherapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Northwest Biotherapeutics' revenue streams: Identify Northwest Biotherapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Northwest Biotherapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Northwest Biotherapeutics' growth potential: Evaluate Northwest Biotherapeutics' management, business model, and growth potential.
- Determine Northwest Biotherapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Northwest Biotherapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Northwest Biotherapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 948.4 M | |
| Retained Earnings | -1.2 B | |
| Retained Earnings Total Equity | -1.2 B |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.